Survodutide by Dragon Pharma
What Is Survodutide?
Survodutide from Dragon Pharma is a metabolic research peptide in the incretin family, supplied as 10 mg of lyophilized powder per vial. It is a dual agonist that activates both GLP-1 receptors and glucagon receptors, a mechanism that has drawn attention in clinical research for weight management and for metabolic liver conditions because it targets appetite and energy expenditure at the same time.
What makes survodutide different from single-pathway peptides is the glucagon side of the mechanism. GLP-1 signaling quiets appetite and slows gastric emptying, while glucagon signaling is tied to energy burn and fat utilization. Research interest in survodutide sits exactly in that combination, and it is the reason it is studied at weekly subcutaneous doses rather than daily ones.
Dragon Pharma supplies survodutide as a laboratory peptide. It is not an approved drug, it is not a steroid, and it belongs in research protocols that include sterile reconstitution, a proper dose schedule and attention to the gastrointestinal effects the class is known for.
Survodutide Research Use
Survodutide research protocols follow the clinical dosing pattern of one subcutaneous injection per week. Doses in the trials are reported in milligrams, not micrograms, and they climb slowly so the digestive system can adapt.
| Phase | Weekly dose | Note |
|---|---|---|
| Start | 0.3 mg | First injection, adaptation begins |
| Step up | 0.6-1.2 mg | Each level held for about 4 weeks |
| Target range | 2.4-4.8 mg | Doses studied in clinical trials |
| Frequency | Once weekly | Same weekday, subcutaneous |
| Vial | 10 mg | Multiple weekly doses per vial |
Reconstitution
Reconstitution follows the standard peptide method: add bacteriostatic water to the vial and measure each dose with an insulin syringe. Because the class is known for nausea and appetite loss, research protocols start low, escalate slowly and stop advancing if gastrointestinal tolerance becomes a problem.
Survodutide Stacks
In research settings survodutide is usually run as a single agent, so the table below lists Dragon Pharma peptides and supports that researchers pair with metabolic work or keep as alternatives in a fat-loss panel.
| Stack partner | Role in the stack |
|---|---|
| Tirze-Pep 10mg | Dual incretin peptide for comparative metabolic research |
| Mazdutide | Alternative dual-pathway metabolic peptide |
| Cagrilintide | Amylin-class appetite research peptide |
| AOD 9604 5 mg | Fat-metabolism fragment for adjunct research |
| MOTS-c 10mg | Mitochondrial and metabolic efficiency |
| L-Carnitine 500 | Fat transport support without receptor overlap |
| Bacteriostatic water | Sterile reconstitution of the lyophilized vial |
Stacking two strong incretin peptides in one protocol is not a common research design because the appetite and gastrointestinal effects overlap. Most researchers choose one primary metabolic peptide and keep the rest of the panel to non-receptor supports.
Survodutide Side Effects
The side effects most often reported in survodutide research come from the incretin mechanism itself and are gastrointestinal.
- Nausea and vomiting: the most reported effect, usually tied to dose and to how fast it is raised.
- Appetite loss: expected from the mechanism; food intake can drop sharply in research subjects.
- Digestive slowing: delayed gastric emptying can cause fullness, bloating and constipation.
- Injection site: mild local reaction is possible with weekly subcutaneous dosing.
- Blood sugar: appetite peptides can lower glucose; monitoring matters in fasted protocols.
Research peptide sold for laboratory and research purposes only. Not intended for human consumption, diagnosis or treatment. This text is not medical advice.
What is survodutide?
Survodutide is a research peptide that activates both GLP-1 and glucagon receptors. Dragon Pharma supplies it as a 10 mg lyophilized vial for subcutaneous research protocols.
How does survodutide work?
It combines two signals in one molecule: GLP-1 activity reduces appetite and slows digestion, while glucagon activity is linked to energy expenditure and fat utilization. That dual mechanism is the focus of its metabolic research.
What is survodutide used for in research?
Research interest centers on weight management and on metabolic liver conditions. In a lab setting it is studied for appetite control, energy balance and body composition endpoints.
What is the survodutide dosage?
Clinical protocols use once-weekly subcutaneous doses starting at 0.3 mg and escalating through 0.6, 1.2, 2.4 and up to 4.8 mg, with each level held for about four weeks.
How often is survodutide injected?
Once per week on a fixed schedule is the clinical pattern. It is dosed in milligrams and measured with an insulin syringe after reconstitution.
How long does survodutide take to show results?
In clinical research, meaningful weight change is reported over weeks to months, and higher maintained doses produce the larger effects. It is not an acute compound.
What are the side effects of survodutide?
Gastrointestinal effects dominate, especially nausea, vomiting, diarrhea and constipation. Appetite loss and digestive slowing are expected from the mechanism and are managed with slow dose escalation.
Is survodutide approved by the FDA?
No. Survodutide is an investigational compound still in clinical trials as of the latest available data. Dragon Pharma sells it strictly as a laboratory research peptide.
How do you reconstitute survodutide?
Add bacteriostatic water to the 10 mg lyophilized vial and swirl gently until the powder dissolves. The reconstituted solution is kept cold and dosed by insulin syringe.
Is survodutide a steroid?
No. It is a dual GLP-1 and glucagon receptor agonist peptide used in metabolic research, completely different in class and mechanism from anabolic steroids.
Related Products
